Biohaven Ltd BHVN

$12.87 -0.27 (-2.05%)

Valuation

Market cap
1,984,718,000
Revenue TTM
$0
Net income TTM
$-738,820,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
21.23

Trading

Volume
1,735,500
Avg volume
2,789,702
Day's range
$12.63 – $13.51
Shares out
151,044,000
Stochastic %K
15%
Beta
1.35
Analysts
Strong Sell
Price target
$21.27

Price

Company profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for...

Show more

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Industry
Biotechnology
Sector
Healthcare
Phone
203 404 0410
Website
https://www.biohaven.com
Address
215 Church Street, New Haven, United States

Latest news

Stocktwits

Timefortendies77 Oct 2, 5:37 PM
$BHVN So the entire market is up, and the shorts just play games hammering down? Get it while you can because the bulls will win in the end. You know the trial results are coming.
0 replies
Timefortendies77 Sep 30, 9:13 PM
$BHVN Love that 6 cents!
0 replies
Timefortendies77 Sep 30, 1:13 PM
$BHVN Reminder-the Obesity Trial finished first week of Sept. We are now going into readout month this week. In addition, we are looking forward to BHVN submitting their updated data in Oct to solve the Rat metabolite issue--there should be an update when they submit.
0 replies
ChrisBAB Sep 29, 7:21 PM
$BHVN https://ir.biohaven.com/news-releases/news-release-details/biohavens-clinical-data-bhv-1530-novel-fgfr3-directed-adc
0 replies
Valueforall Sep 29, 6:31 PM
$BHVN just a simple lesson on why it’s important to spot minis early before they turn into biggies!
0 replies
Valueforall Sep 29, 5:41 PM
$BHVN boner& alert ‼️
0 replies
Timefortendies77 Sep 29, 12:52 PM
$BHVN Here we go again, force down Pre, then drop the hammer at 9:30, then release the hammer around 10 and start climbing again. Rinse, repeat--except any times news drops it changes that flow.
0 replies
Valueforall Sep 28, 4:30 PM
$BHVN ok now it’s time for the daily poll question 🙋‍♂️ Who wer this mornings dip buyers and who were this AM’s pus&sy surveyors ? Please no pushing and shoving. Form a line and submit your response and own it. Transparency matters 🪦 Nitin
2 replies